Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| Global Epilepsy Drugs Market Report 2019 Featuring Eisai, UCB, H. Lundbeck A/S, and GW Pharmaceuticals | ||
| By: PR Newswire Association LLC. - 12 Feb 2019 | Back to overview list |
|
DUBLIN, Feb. 12, 2019 /PRNewswire/ -- The "Epilepsy Drugs Market by Country (US, UK, France, etc), Drugs (Vimpat, Keppra, Sabril, Onfi, etc), Treatment Drugs Generation (First, Second, Third), Companies & Forecast" report has been added to ResearchAndMarkets.com's offering. The global epilepsy drugs market is expected to cross US$ 9 Billion landmark by 2025. Epilepsy can develop in both males and females of all races, ethnic backgrounds, and ages. It affects around 65 Million people globally. The United States has around 3.4 Million epilepsy patients; among them around 470 Thousand are children. Epilepsy prevalence varies across various parts of the world. At present, nearly one-third of the total patients are suffering from uncontrollable seizures and are not able to get treatment because no available treatment works for them. The factors that are driving the global Epilepsy drug market are increasing epilepsy prevalence, growing patient awareness programs, government funding and drugs reimbursement options in European & American countries. Recently, anti-epilepsy drugs Epidiolex approvals for pediatric epilepsies, namely Lennox-Gastaut syndrome and Dravet syndrome in the United States will also help in the growth of Epilepsy drug market during the forecast period as well. By Country - United States is Dominating Global Epilepsy Drugs Market The report studies the market of the following countries: United States, United Kingdom, France, Germany, Italy, Spain, India, China, and Japan. The United States is dominating the global epilepsy drugs market. Its share is expected to grow in the years to come due to the better healthcare support system, growing awareness and increasing per capita healthcare expenditure. By Drugs - Vimpat (Lacosamide), Keppra (Levetiracetam) and Epidiolex are playing a significant role The report studies the market of the following drugs: Vimpat (Lacosamide), Keppra (Levetiracetam), Sabril (Vigabatrin), Onfi (Clobazam), Fycompa, Briviact (Brivaracetam), Epidiolex, Cenobamate (YKP3089). At present, Vimpat (Lacosamide) and Keppra (Levetiracetam) are playing a significant role in the epilepsy treatment. Epidiolex has a bright future ahead. By Drugs Category - Second and Third Generation Plays the Significant Role In this report, we have categorized the epilepsy drugs market into three generations; First Generation, Second Generation, Third Generation. It is anticipated that the second and third generation plays a significant role in the global epilepsy drugs market during the forecast period of 2019-2025. Company Analysis Eisai Co., Ltd, UCB Inc., H. Lundbeck A/S, and GW Pharmaceuticals Plc. are some of the top companies that deal efficiently in epilepsy business globally. These companies have been studied thoroughly in the report. Key Topics Covered: 1. Introduction For more information about this report visit https://www.researchandmarkets.com/research/dzmnf7/global_epilepsy?w=5 Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets
SOURCE Research and Markets 
|
||
|
|
||
 | Back to overview list | |
View original content: